Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose IL-2 in SLE Patients With CMV Viremia
NCT06971913Phase 2Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- May 2025
- Primary completion
- Sep 2025
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of aldesleukin in systemic lupus erythematosus (SLE), cytomegalovirus infection (CMV), sponsored by Peking University People's Hospital. Planned start May 2025; status: not yet recruiting.
02
Drugs
aldesleukin
03
Conditions
systemic lupus erythematosus (SLE)cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT06971913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06971913.